– Report details the company's commitment to
improve healthcare for all through its ESG and sustainability
initiatives –
SAN
FRANCISCO, April 17, 2023 /PRNewswire/
-- Invitae (NYSE: NVTA), a leading medical genetics company,
today published its 2023 Environmental, Social and Governance (ESG)
Report. This report provides a holistic view of the company's
approach to ESG and our performance and progress through measurable
data and metrics during the 2022 fiscal year.
"We continue to be committed to advancing our sustainable
business practices and ESG efforts as part of our core mission to
bring comprehensive genetic information into mainstream medicine,"
said Erik Kaiser, chief
sustainability officer. "This year's report demonstrates how
Invitae's purpose and values guide our goal of improving healthcare
for all, upholding our social responsibility, exercising
environmental stewardship and governing with trust and transparency
throughout our business."
The report provides an in-depth review of the progress made in
the past year through company-wide ESG initiatives. The company's
notable achievements include:
- Continued our focus on increasing the utility of genetics for
underrepresented populations by conducting clinical research and
advancing Invitae's Ciitizen platform to allow patients to share
their genetic information for research. We are proud to be
supporting clinicians and researchers to better understand how
cancer and rare disease uniquely impact individuals of diverse
ancestries with our data platform and patient network.
- Published an inaugural and first-of-its kind Data Use
Transparency and Impact Report that details how the company has
used patient data to advance precision medicine, demonstrating a
commitment to ethical data stewardship.
- Advocacy efforts for expanded access to genetic testing that
resulted in policies and professional clinical guidelines that
qualify more patients and their families for genetic testing. We
released new data and commentary that supports universal germline
testing for all patients with cancer and worked to remove
restrictive guidelines that would open up access and affordability
to genetic testing.
- Four Invitae core laboratories (San
Francisco, Irvine,
Metropark and Sydney, Australia)
achieved accreditation by the International Organization for
Standardization (ISO) for Clinical Laboratories ISO 15189. This
distinction validates the company's dedication to continuous
quality improvement for patients.
- Scope 1 and Scope 2 greenhouse gas (GHG) emissions collection
that informed and progressed our energy and climate strategy.
"It gives me great pride to share our 2023 ESG Report
highlighting the progress we have made in advancing our
environmental initiatives, social responsibility commitments and
governance framework," said Ken
Knight, president and chief executive officer of Invitae.
"We believe our long-term business and ESG strategies are
interdependent and start with our unique, patient-first
culture."
Invitae's full 2023 ESG Report can be downloaded here.
About Invitae
Invitae (NYSE: NVTA)
is a leading medical genetics company trusted by millions of
patients and their providers to deliver timely genetic information
simplified by digital technology. With accurate and actionable
answers to strengthen medical decision-making, Invitae
gives individuals and their families powerful, personalized
insights that could improve and extend their lives.
Invitae's genetics experts apply a rigorous approach to data
and research, serving as the foundation of their mission to bring
comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people.
To learn more, visit invitae.com and follow for
updates on Twitter, Instagram, Facebook and LinkedIn
@Invitae.
Safe Harbor Statement
This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the company's ESG and
sustainability plans and initiatives and the expected impact
thereof. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: the impact of inflation and the current
economic environment on the company's business; the company's
ability to grow its business in a cost-efficient manner; the
company's history of losses; the company's ability to maintain
important customer relationships; the company's ability to
compete; the company's need to scale its infrastructure in advance
of demand for its tests and to increase demand for its tests; the
applicability of clinical results to actual outcomes; risks
associated with litigation; the company's ability to use rapidly
changing genetic data to interpret test results accurately and
consistently; security breaches, loss of data and other
disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Annual Report on Form 10-K for the year
ended December 31, 2022. These
forward-looking statements speak only as of the date hereof,
and Invitae Corporation disclaims any obligation to
update these forward-looking statements.
Invitae PR contact:
Amanda McQuery
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-publishes-annual-environmental-social-and-governance-esg-report-301799299.html
SOURCE Invitae Corporation